Mexican drug cartels may now reportedly be using weaponised drones with remote detonators.On 20 October, Mexican police pulled over four men in a pickup truck near the city of Salamanca in Guanajuato state and found that the men had an AK-47 rifle, an unmanned aerial vehicle (UAV) outfitted with a "large explosive device" and a remote detonator in their possession.Although Mexican authorities refrained from clarifying whether the four men had any ties to drug cartels, according to Dr Robert Bunker, a fellow with Small Wars Journal, Guanajuato is at present considered to be a contested area, with several drug gangs, including the Sinaloa cartel, Los Zetas, and Cártel Jalisco Nueva Generación (CJNG) operating in the state.However, it appears that the use of weaponised drones by drug cartels may not have been too surprising, given how some cartels are known to have previously used drones to smuggle drugs."This has been expected for some time now," Bunker told Motherboard.Rival drug cartels have also reportedly used "potato bombs" – hand grenade-sized IEDs – in attacks against each other and against the authorities.
The news heavyweight may stand out on the youthful social media app, but it has drawn over 7 million viewers per month, according to the publisher, with editions that educate readers on serious topics like globalization’s losers or the war on drugs.Those editions are built by Lucy Rohr, a veteran digital producer and editor at The Economist.“I don’t think we’ve come up with the Economist Snapchat secret-sauce recipe yet,” Rohr said.I read the Axios newsletter and, Wi-Fi permitting, look at the headlines elsewhere.I find it interesting to compare the front pages of The New York Times with what Fox has up.8:30 a.m.: Our Snapchat team is based in Bucharest, Romania, and London, so I spend much of my morning in New York online with them before they log off.
ANN ARBOR -- In a study that could provide a roadmap for combatting the rising threat of drug-resistant pathogens, researchers have discovered the specific mechanism the body's T cells use to kill bacteria.University of Michigan researchers, in collaboration with colleagues at Harvard University, have discovered a key difference between the way immune cells attack bacteria and the way antibiotics do.It's a study with potential implications for drug-resistant pathogens--a problem projected to kill as many as 10 million people annually across the globe by the year 2050."We have a huge crisis of antibiotic resistance right now in that most drugs that treat diseases like tuberculosis or listeria, or pathogens like E.coli, are not effective," said Chandrasekaran, U-M assistant professor of biomedical engineering.Killer T cells, formally known as cytotoxic lymphocytes, attack infected cells by producing the enzyme granzyme B.Chandrasekaran and his team monitored how T cells deal with three different threats: E. coli, listeria and tuberculosis.
PHOENIX and LOS ANGELES -- Oct. 26, 2017 -- Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California (USC).Precision Medicine using this type of tumor-only approach, as a means of guiding therapeutic intervention, is more precise for those of European decent, and less precise for those whose ancestry is from Latin America, Africa and Asia, according to the study published online Oct. 19 in the scientific journal BMC Medical Genomics.Most of the tens of thousands of individuals worldwide who have undergone whole-genome sequencing -- the spelling out of the nearly 3 billion chemical bases in their DNA -- are of European decent, biasing existing databases used to exclude false-positive variants.But when those aren't available, we need better tools and this is where we have put our focus," said Dr. David W. Craig, Vice Chair of the Keck School of Medicine of USC's Department of Translational Genomics and the study's senior author."There is a growing body of knowledge on the shortfalls of Precision Medicine," said Dr. Rick Kittles, Professor and Founding Director of the Division of Health Equities, Department of Population Sciences, at City of Hope, and one of world's foremost scientists in the area of population genetics and cancer."This study goes beyond the barriers to participation and provides insight on the lack of genetic data from diverse populations and its impact on the value and utility of Precision Medicine.
The Government has come under pressure after Panorama exposed how one private contractor failed to take action on more than 15,000 missed appointments over 16 months in London, according to internal documents seen by the BBC’s reporters.Nadine Marshall’s son Conner, 18, died following a brutal attack in Porthcawl, south Wales, in 2015.David Braddon, a 26-year-old man from Caerphilly who murdered Conner, was being monitored by probation workers after being convicted for drugs offences and assaulting a police officer.“It was just devastation ... it was just horrific to learn he was known and the whole case was a shambolic state.”The programme also revealed how five-year-old Alex Malcolm was murdered by a violent criminal, Marvyn Iheanacho, put on probation in London.His mother, Liliya Breha, told Panorama how no-one from the government-run National Probation Service (NPS) had told her about his conviction despite Iheanacho having a history of violence dating back to 1994.
Report from dark web firm Intsights said Tor's ORbot used to launch new markets.The analysis was based on data taken from thousands of black markets, hacking forums, messaging apps and social media between July 2016 and July 2017.The Intsights team found mobile dark web activity was spiking, with many people using mainstream services like Discord, Telegram and WhatsApp to trade illicit goods – including credit cards, breached records, hacking tools and illegal drugs."Our findings suggest Discord is becoming the go-to-app for mobile dark web discussions," the team said, referencing the chat service typically used by gamers.The firm said they are often "small and distributed networks" which can be destroyed quickly."The anonymity promised by dark web networks such as TOR and i2p was the key reason for their popularity among cybercriminals," said Guy Nizan, IntSights co-founder and CEO. founder and CEO Jeff Bezos presents the company's first smartphone, the Fire Phone, on June 18, 2014 in Seattle, Washington.The much-anticipated device is available for pre-order today and is available exclusively with AT service.We just got another hint that Amazon is getting into healthcare.Samantha Liss at the St. Louis Post-Dispatch reports that Amazon has been approved for wholesale pharmacy licenses for at least 12 states.That's based on regulatory filings reviewed by the Post-Dispatch.While the licenses don't necessarily indicate that Amazon is going to start to sell prescription drugs, the news was enough to make the stocks of some of the major players in the pharmaceutical supply chain move.
HOUSTON - (Oct. 26, 2017) - A breakthrough discovery by scientists at Houston Methodist could change the way we treat cholesterol.This accidental discovery, made by medical biochemist Henry Pownall, Ph.D., and his team at the Houston Methodist Research Institute, reveals a new pathway in the cholesterol-elimination chain that will be key to developing new drugs to lower cholesterol.Their findings are described in an article titled "ABCA1-Derived Nascent High Density Lipoprotein-Apo AI and Lipids Metabolically Segregate," appearing online Oct. 26 and in print Nov. 21 in the American Heart Association's Arteriosclerosis, Thrombosis, and Vascular Biology journal."The model people have been using for 40 years presumed that cholesterol was transported from the arteries with other lipids and proteins and entered a particle that stayed in the blood for several days before being cleared by the liver for disposal," Pownall said.Cholesterol in the nascent HDL goes directly to the liver, largely skipping conversion to the mature form of HDLPownall stresses that it's not that current practices of treating "bad" LDL cholesterol are incorrect, but instead that physicians and researchers need to better understand how the "good" HDL cholesterol contributes to cardiovascular disease and how to raise it in a way that protects the heart, because some patients with very high HDL numbers, which were always thought to be beneficial, are actually at risk.
Parexel International will use Microsoft Azure to accelerate clinical trials and enhance patient engagementMicrosoft and Parexel International, a biopharmaceutical services company, have partnered to create cloud-based services aimed at helping pharmaceutical firms speed up the delivery of new drugs and therapies.Under the terms of the alliance, Microsoft Azure becomes Parexel’s preferred cloud platform, similar to deals the Redmond, Wash. software giant has struck with Adobe and SAP SuccessFactors.Together, Microsoft and Parexel will explore ways of helping the industry advance the field of precision medicine.They also plan on building systems that promote making clinical trials participation more accessible and improve patient engagement, the two companies said in an Oct. 24 announcement.“Drug development is becoming more complex, while innovations including social media, analytics, mobile technology and the Internet of Things are enabling a more patient-centric approach,” Xavier Flinois, president of Parexel Informatics, the company’s technology subsidiary, said in a statement.
The research, which appears in the journal Biological Psychiatry, finds that the use of compounds called positive allosteric modulators, or PAMs, enhances the effect of pain-relief chemicals naturally produced by the body in response to stress or injury."Our study shows that a PAM enhances the effects of these pain-killing chemicals without producing tolerance or decreased effectiveness over time, both of which contribute to addiction in people who use opioid-based pain medications," said Andrea G. Hohmann, a Linda and Jack Gill Chair of Neuroscience and professor in the IU Bloomington College of Arts and Sciences' Department of Psychological and Brain Sciences, who led the study.1 cause of death for Americans under 50, outranking guns and car accidents and outpacing the HIV epidemic at its peak.Medical researchers are increasingly studying positive allosteric modulators because they target secondary drug receptor sites in the body.By contrast, "orthosteric" drugs -- including cannabinoids such as delta-9-tetrahydrocannabinol (THC) and opioids such as morphine -- influence primary binding sites, which means their effects may "spill over" to other processes in the body, causing dangerous or unwanted side effects.Rather than acting as an on/off switch, PAMs act like an amplifier, enhancing only the effects of the brain's own natural painkillers, thereby selectively altering biological processes in the body that naturally suppress pain.
CORAL GABLES, FL (October 16, 2017) - A probe invented at Rice University that lights up when it binds to a misfolded amyloid beta peptide--the kind suspected of causing Alzheimer's disease--has identified a specific binding site on the protein that could facilitate better drugs to treat the disease.Even better, the lab has discovered that when the metallic probe is illuminated, it catalyzes oxidation of the protein in a way they believe might keep it from aggregating in the brains of patients.The study done on long amyloid fibrils backs up computer simulations by colleagues at the University of Miami that predicted the photoluminescent metal complex would attach itself to the amyloid peptide near a hydrophobic (water-avoiding) cleft that appears on the surface of the fibril aggregate.Finding the site was relatively simple once the lab of Rice Chemist Angel Martí used its rhenium-based complexes to target fibrils.The light-switching complex glows when hit with ultraviolet light, but when it binds to the fibril it becomes more than 100 times brighter and causes oxidation of the amyloid peptide."It's like walking on the beach," Marti said.
Yet presidents matter for promoting innovation even if it’s less glamorous than taxes.Two of his appointees in particular, Food and Drug Administration Commissioner Scott Gottlieb and Federal Communications Commission Chairman Ajit Pai, have prioritized reducing regulatory hurdles to private investment as a way of boosting innovation.Though vocal advocates of slashing the corporate tax rate, their bigger problem is the staggering cost of development: $2.6 billion on average to bring a new drug to market, once the cost of capital and failed drugs is included, according to Tufts University’s Center for the Study of Drug Development.That, he says, is appropriate if it means drugs are more likely to be safe and effective.Aaron Kesselheim, a doctor specializing in drug research at Harvard Medical School, noted the FDA had been improving the efficiency of drug reviews before Mr. Gottlieb arrived.Still, Michael Yee, an analyst with Jefferies LLC., says Mr. Gottlieb’s verbal commitment to more flexible approval requirements and patient input signaled important shifts.
People taking blood-thinning drugs against atrial fibrillation can also halve the risk of dementia, according to a new study from the Danderyd hospital."blood thinning drugs not only reduces the risk of stroke in patients with atrial fibrillation.We can also see a significant reduction in the risk of dementia," says professor Mårten Rosenqvist in a press release.Almost a half a million people from the national patient register have been studied.Those who took blood-thinning drugs at the outset of the study 29 percent more likely to develop dementia.Of those who continued taking the drugs, the risk declined by 48 per cent.
The common understanding of diabetes mellitus includes two types: type one and type two.Type 3c diabetes, or “Diabetes of the Exocrine Pancreas,” is a third type caused by pancreatic damage.But a recent study found that doctors were likely misdiagnosing this form of diabetes as type 2.“Several drugs used for type 2 diabetes, such as gliclazide, may not be as effective in type 3c diabetes,” Andrew McGovern from the University of Surrey wrote in The Conversation.“Misdiagnosis, therefore, can waste time and money attempting ineffective treatments while exposing the patient to high blood sugar levels.”Scientists have recognised other types of diabetes aside from type-1 (the body destroys its own insulin-producing cells) or type-2 (the body can’t make enough insulin) for a long time.
The common understanding of diabetes mellitus includes two types: type one and type two.Type 3c diabetes, or “Diabetes of the Exocrine Pancreas,” is a third type caused by pancreatic damage.But a recent study found that doctors were likely misdiagnosing this form of diabetes as type 2.“Several drugs used for type 2 diabetes, such as gliclazide, may not be as effective in type 3c diabetes,” Andrew McGovern from the University of Surrey wrote in The Conversation.“Misdiagnosis, therefore, can waste time and money attempting ineffective treatments while exposing the patient to high blood sugar levels.”Scientists have recognised other types of diabetes aside from type-1 (the body destroys its own insulin-producing cells) or type-2 (the body can’t make enough insulin) for a long time.
New Rochelle, NY, Oct. 24, 2017 -- As the brain has limited capability for self-repair or regeneration, stem cells may represent the best therapeutic approach for counteracting damage to or degeneration of brain tissue caused by injury, aging, or disease.Although preclinical testing of stem cell therapies has shown promise, results achieved in animals are not necessarily indicative of what will occur in patients, and clinical studies in humans have been limited in size and number.The potential value of stem cells and emerging therapeutic agents in neurodegenerative diseases are the focus of an article published in Rejuvenation Research, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.The article is available free on the Rejuvenation Research website until November 24, 2017.Martina Nasello, Giuseppe Schirò, Floriana Crapanzano, and Carmela Rita Balistreri, University of Palermo, Italy, review the published literature and the most recent data evaluating the effectiveness of stem cells and other potential therapeutic compounds in the prevention and treatment of neurodegenerative pathologies.They describe their findings in the article entitled "Stem Cells and Other Emerging Agents as Innovative 'Drugs' in Neurodegenerative Diseases: Benefits and Limitations."
Oct. 24, 2017, WASHINGTON, D -- NEHI (the Network for Excellence in Health Innovation) called today for a series of regulatory steps and other actions to enable new payment arrangements for high cost cancer drugs.Known as "value-based" or "outcomes-based" contracts, such arrangements tie payments to measurable results in patients, in contrast to prevailing arrangements that tie prices and discounts to the volume of drugs purchased.Although value-based contracting itself isn't a total solution to the challenge of high-cost drugs, NEHI argues that it is an "important arrow in the quiver" as health insurers and other payers confront a growing number of these medications.In a white paper published today, NEHI synthesized perspectives from a group of experts across multiple sectors: biopharmaceutical companies, health insurers, pharmacy benefit managers, and patient groups.The paper recommends a number of changes to support thoughtful experimentation in value-based contracting, as follows:Various stakeholders, including the oncology community, payers, and biopharmaceutical manufacturers, should expedite efforts to improve collection of data and should develop patient-reported outcomes measures for cancer care.
A “significant” proportion of patients being put on cholesterol-lowering drugs are deemed to be at low risk of having a heart attack or stroke, a new study suggests.Researchers found there could be “significant over-treatment” of statin therapy among patients who have less than a 10% chance of developing cardiovascular disease (CVD) within 10 years.The study, published in the British Journal of General Practice, tracked statin prescribing over a period of time.Researchers from the University of Birmingham looked at data from 1.4 million patients aged over 40 across 248 GP practices across England and Wales between 2000 and 2015.Over this time period, 217,860 patients started statin treatment.Among all patients, 151,788 were recorded as having undergone the recommended risk assessment for CVD.
Today, Google is looking into reports of OLED screen burn-in on its new phones, a fifth of antibiotic prescriptions in England are unnecessary, a major new Facebook trial eliminates non-promoted posts from its News Feed and more.Get WIRED Awake sent straight to your inbox every weekday morning by 8am.Some reports indicate that the after-images disappear after a few seconds, as compared to standard screen burn-in, which is permanently etched on a display.Public Health England has warned that up to a fifth of prescriptions for antibiotics are unnecessary, contributing to the dangerous rise of antibiotic-resistant bugs in the UK (BBC News).The new Keep Antibiotics Working campaign aims to engage patients in the effort to reduce antibiotic use by urging them to follow doctors' guidance rather than asking for the drugs.The trial, which is taking place in six countries, gives users two feeds: one for friends, family and content Page owners have paid to promote, and the other for all other posts by Pages.
You might say the United States is a nation of pill poppers.Many adults take at least one prescription drug, but it’s not uncommon for older people to be on five or more medications, according to the Centers for Disease Control and Prevention.Without insurance, the cost may feel so exorbitant you may be tempted to skip or skimp on medication.Unfortunately, with the way our healthcare system is set up, it can be tough to comparison shop—even your doctor may not know what you’ll end up paying for a prescription.But that doesn’t mean he or she doesn’t want to help you out.So if there’s even a small chance you may skip the script because of money trouble, it’s better to say so and work on solutions together.)Even with insurance, drugs can be pricey. Without insurance, the cost may feel so exorbitant you may be tempted to skip or skimp on medication. Don’t. There are ways to rein in the cost of prescription drugs, and skipping medication can be disastrous and ultimately more costly than the drugs themselves. Original post : Prescription Medication Costs